IL6, interleukin 6, 3569

N. diseases: 2367; N. variants: 22
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 AlteredExpression phenotype BEFREE Advanced cancers are associated with a chronic inflammation, especially high interleukin-6 (IL-6) and with various levels of adipokines (leptin and adiponectin), while ghrelin counteracts the anorexigenic effect of leptin in cancer-induced anorexia-cachexia syndrome. 31794851 2020
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE We previously found that the human TOV21G cells secrete IL-6 that induces autophagy in reporter cells and cachexia in mice. 31436048 2020
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 AlteredExpression phenotype BEFREE The metabolic reduction in cachectic cancer patients was potentially related to the elevated serum level of interleukin-6. 30713247 2019
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Lastly, the correlations between plasma interleukin-6 (IL-6) and lipid metabolism parameters in cachexia patients of different genders were analyzed. 31788012 2019
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE In cancer, the pro-inflammatory cytokine interleukin-6 (IL-6) is considered a mediator of cachexia and a potential biomarker, but the relationship between IL-6, weight loss, and cancer stage is unknown. 30497874 2019
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 AlteredExpression phenotype BEFREE Systemic IL-6 overexpression in precachectic tumor-bearing Apc<sup>Min/+</sup> mice accelerated cachexia development, which coincided with suppressed basal and eccentric contraction-induced muscle protein synthesis. 29641213 2018
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Based on these findings, we conclude that chronic inflammation (especially that mediated by IL-6) might promote cancer cachexia by regulating WAT lipolysis in early-stage cachexia and browning in late-stage cachexia. 29338749 2018
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 AlteredExpression phenotype BEFREE The serum level of the lipopolysaccharide-binding protein, often presented as a reflection of the bacterial antigen load, was not only increased in cachectic mice and cancer patients, but also strongly correlated with the serum IL-6 level and predictive of death and cachexia occurrence in these patients. 29719601 2018
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Collectively, these preclinical findings identify trans-signalling via STAT3 as the signalling modality by which IL-6 promotes muscle wasting in lung cancer cachexia, and therefore support the clinical evaluation of the IL-6 trans-signalling/STAT3 axis as a therapeutic target in advanced lung cancer patients presenting with cachexia. 27893707 2017
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE This relationship in the female warrants further investigation, as we have shown that the ability of IL-6 to induce cachexia differs between the sexes. 28292759 2017
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 AlteredExpression phenotype BEFREE In lung cancer patients, were cachexia is prevalent, there was a significant correlation between elevated IL-6 expression in the tumor and poor prognosis of the patients. 28515477 2017
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Others and we have shown that IL-6 alone is sufficient to induce cachexia both <i>in vitro</i> and <i>in vivo</i>. 28149280 2016
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 AlteredExpression phenotype BEFREE Overall, these results demonstrate short-term PDTC treatment to cachectic mice attenuated cancer-induced disruptions to muscle and liver signaling, and these changes were independent to altered tumor burden and circulating IL-6. 27449092 2016
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 GeneticVariation phenotype BEFREE The association of SELP-rs6136, IL6-rs1800796 and AKT1-rs1130233 polymorphisms with cachexia as well as the correlation between cachexia and the candidate polymorphisms and overall survival were analyzed. 25238546 2014
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE IL-6 triggers oncogenic/angiogenic signals and the cytokine-dependent pro-cachexia cascade. 24886605 2014
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Clinical trials in non-small cell lung cancer (NSCLC) reveal that IL-6 targeted therapy relieves NSCLC-related anemia and cachexia, although other clinical effects require further study. 24260500 2013
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE A marked increase (5-fold) in IL-6 as a result of the interaction between the presence of cachexia and the presence of tumour was observed in the subcutaneous tissue of the patients, yet not in the visceral depot. 23200412 2013
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Interestingly, signs of morbidity (cachexia) in mice treated with MV were not directly associated with tumour burden, but were correlated with the secretion of interleukin-6 by MET-1 cells and host cells. 21325484 2011
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 GeneticVariation phenotype LHGDN Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. 18469355 2008
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE At the protein level, TNF-alpha was found expressed only in CIX, whereas IL-1 and IL-6 were not cachexia specific. 17878525 2007
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE A highly sensitive ELISA confirmed the multiplex result for increased IL-6 in cachectic patients (P = 0.02). 18006755 2007
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype CTD_human Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention. 17878525 2007
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype LHGDN Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. 17931612 2007
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE However, since release of IL-6 is frequent in HCC, especially in its more advanced stages, the use of agents like curcumin or DHMEQ might be beneficial to counteract its adverse systemic effects (e.g., cachexia). 17261774 2006
CUI: C0006625
Disease: Cachexia
Cachexia
0.600 Biomarker phenotype BEFREE Moreover, IL-6 is a pathophysiological factor in several hyperproliferative diseases and the paraneoplastic syndromes that often accompany cancer, such as cachexia and osteoporosis; thus, anti-IL-6 therapy would be useful in treating these entities as well. 16083340 2005